Xilio Therapeutics, Inc. (XLO) Misses Q2 EPS by 1c

Xilio Therapeutics, Inc. (NASDAQ: XLO) reported Q2 EPS of ($0.24), $0.01 worse than the analyst estimate of ($0.23). Revenue for the quarter came in at $2.4 million versus the consensus estimate of $30 million.

For earnings history and earnings-related data on Xilio Therapeutics, Inc. (XLO) click here.

You May Also Be Interested In

• Needham Starts Red Violet (RDVT) at Buy, 'offers the leading Cloud identity intelligence platform in the market today'
• PG&E downgraded by Wells Fargo, BMO as California wildfire reform falls short
• Getty Realty (GTY) Reiterated at Market Outperform by Citizens Amid Favourable Trends